Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29952981 | 0.98 | ENPP2 (0.46) | ENPP2CA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL29953008 | 0.87 | TUBB4A (0.40) | ENPP2CA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL29636771 | 0.77 | CA1 (0.50) | ENPP2CA1CA2ALDH1A1TUBB4A | |
| SCHEMBL42032 | 0.77 | CA1 (0.50) | ENPP2CA1CA2ALDH1A1TUBB4A | |
| SCHEMBL204912 | 0.77 | PTPN1 (0.38) | ENPP2CA1CA2HPGD | |
| SCHEMBL841371 | 0.76 | ALDH1A1 (0.46) | ENPP2CA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL29952923 | 0.76 | NQO1 (0.46) | ALDH1A1CYP3A4HPGDMEN1KMT2A | |
| SCHEMBL29956410 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HPGDMEN1KMT2ATSHR | |
| SCHEMBL318375 | 0.74 | TAAR1 (0.45) | ENPP2CA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL16532784 | 0.74 | MAPK1 (0.37) | ENPP2HPGDMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-105330642-A | Selenophen compound | INOR WUHAN PHARMACEUTICAL CO LTD | 2016-02-17 | — | — | CN | claimed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4622967-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4585587-A1 | PROPIONIC ACID DERIVATIVE AND USE THEREOF IN MEDICINE | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20060237368-A1 | Twisted pi-electron system chromophore compounds with very large molecular hyperpolarizabilities and related compositions and devices | NATIONAL SCIENCE FOUNDATION | 2006-10-26 | — | — | US | disclosed |
| WO-2006102620-A2 | TWISTED π-ELECTRON SYSTEM CHROMOPHORE COMPOUNDS WITH VERY LARGE MOLECULAR HYPERPOLARIZABILITIES AND RELATED COMPOSITIONS AND DEVICES | NORTHWESTERN UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | ENPP2 1856/4885CA1 3214/4885CA2 247/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ENPP2 1064/4885CA1 4115/4885CA2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.